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There is increasing experimental evidence that the 
neurologic system can directly participate in cutane­
ous in1lammation and wound healing. Recent studies 
indicate that neuropeptides released by cutaneous 
nerves such as c-fibers can activate a number of tar­
get cells including keratinocytes, Langerhans cells, 
mast cells, and endothelial cells. One such neuropep­
tide, substance P (SP), is able to specifically bind to 
murine and human keratinocytes and induce the 
release of cytokines such as interleukin 1 (IL-l). 
Other studies demonstrate that SP can also activate 
mast cells to produce the potent pro-inflammatory 
cytokine tumor necrosis factor a (TNFa). More re­
cently, we examined the effect of cutaneous neu­
ropeptides on human dermal microvascular endothe-
NEUROGENIC INFLAMMATION 
It has been appreciated by dennatologists for many years that the 
skin is a complex tissue with a sophisticated cutaneous neurologic 
system and specialized afferent sensory structures capable of elicit­
ing the sensation of pain, itch, light touch, vibration, heat, and cold. 
It is less well known that this sensory system also is capable of 
efferent activities in the skin. Recent studies indicate that neuropep­
tides released by sensory nerves in the skin are capable of activating 
specific cutaneous target cells to induce a range of inflammatory 
activities (Baraniuk et ai, 1990; Bernstein, 1991; Payan, 1992; Eedy, 
1993; Hosoi et ai, 1993; Pincelli et ai, 1993; Ansel et ai, 1996). 
In the early part of this century, Bayliss and Bruce noted that 
patients with defective cutaneous sensory systems were not capable 
of mounting a nonnal inflammatory responses in the skin to 
topically applied irritants (Bayliss, 1901). Likewise, clinicians noted 
that patients with congenital analgesia syndromes, post-herpes 
analgesia, and diabetic neuropathy have defective inflammatory 
responses in the skin (Lewis and Marvin, 1927; Lewis, 1927). These 
types of clinical observations led investigators to examine the role 
of the neurologic system in modulating inflammatory responses in 
the skin. It remained to be determined, however, how the neuro­
sensory system was able to participate in cutaneous inflammation. 
The search for a link between the neurologic system and the 
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lial cell (HDMEC) activities. Our studies indicate that 
the c-fiber-derived calcitonin gene-related peptide 
(CGRP) is capable of stimulating HDMEC to secrete 
the neutrophil chemotactic factor interleukin 8 (IL-
8). In addition, SP is able to directly activate HDMEC 
to express high levels of the important cellular adhe­
sion molecule vascular cellular adhesion molecule 1 
(VCAM-l). Thus, these studies support the role that 
the neurologic system may play in mediating the 
biologic processes that occur during inflammation 
and wound healing in the skin. Key words: neuropep­
tides/substance P/keratinocytes/wound healing. Journal of 
Investigative Dermatology Symposium Proceedings 2:23-26, 
1997 
inflammatory process in the skin soon focused on neuropeptides 
released by nerves such as c-fibers. Although these small peptides 
principally act as neurotransmitters, suggestive evidence supported 
their role as mediators of inflammation. Investigators detected 
increased levels of neuropeptides and their respective receptors in 
inflamed tissues (Levine et ai, 1984; Holzer, 1988). In addition, 
certain neuropeptide antagonists had anti-inflammatory properties 
in experimental animal models of inflammation (payan, 1992). The 
precise mechanism by which the activated nerves mediated inflam­
matory responses, however, was still unclear. 
To explain the pro-inflammatory interaction between nerves and 
tissue target cells, the axon-reflex model of neurogenic inflamma­
tion was proposed. This model proposes that when any tissue 
innervated by the sensory nervous system is injured, an immediate 
orthodromic signal is elicited by the sensory nerves from this tissue 
to the dorsal root ganglia and to the central nervous system, 
allowing the host to quickly sense and respond to the injury. In 
addition to this orthodromic response, the sensory nerves are 
capable of a second impulse in the reverse direction back to the 
innervated tissue--the so called antidromic response (Holzer, 
1988). With this antidromic response, neuropeptides are released 
into the injured tissue and may interact with potential target cells 
located in close proximity to the activated nerve fibers (Holzer, 
1988; Payan, 1992). This hypothesis presented another potential 
problem for investigators because it was believed that only nerves 
had specific receptors for these neurotransmitters. 
NEUROPEPTIDE RECEPTORS AND DEGRATOR Y 
ENZYMES IN NONNEURONAL TISSUE 
A further breakthrough in this field occurred when it was discov­
ered that a number of nonneuronal-derived cells had receptors for 
1087-0024/97/$10.50 • Copyright © 1997 by The Society for Investigative Dermatology, Inc. 
23 
24 ANSEL ET AL 
these secreted neuropeptides and could be activated by some 
neuropeptides. Investigators reported that ly�phoid cells such as T 
cells B cells and monocytic cells have specific receptors for these 
neu:otransnrltters (Helke et ai, 1990; Tsuchida et ai, 1990). In 
addition. it was noted that immunologic tissues such as lymph 
nodes, spleen, and thymus were innervated by small nerves capable 
of secreting a wide range of neuropeptides (Hadden et aI, 1977; 
Payan, 1992). Therefore, the principal lymphoid organs are hard­
wired to the neurologic system, which is capable of activating 
resident leukocytes via the release of cutaneous neurotransmitters. 
Recent research also indicates that when these immune cells are 
exposed to specific neuropeptides, they become activated effector 
cells and demonstrate increased cytotoxic activities, antibody se­
cretion, and cytokine production (Hartung and Toyka, 1983; Payan 
et ai, 1983; Hartung et ai, 1986; Payan and Goetzl, 1988; Wieder­
man et ai, 1989; McGillis et ai, 1991; Pascual et ai, 1991; Calvo et ai, 
1992). Thus, in a very direct way the neurologic system can mod­
ulate immune responses. 
In addition to lymphoid cells, a wide range of nonimmune cells 
also express receptors for neurotransmitters. In the skin both 
epidermal and dermal cells express receptors for neuropeptides 
(Brown et ai, 1990; Matis et ai, 1990; Greeno et ai, 1992; Ansel et ai, 
1993). It has been demonstrated that cutaneous sensory fibers are in 
close contact not only with dermal blood vessels, mast cells, and 
fibroblasts but extend up into the epidermis where they are in 
intimate contact with both keratinocytes and Langerhans cells 
(Dalsgaard et ai, 1989; Hosoi et ai, 1993). Thus, in the skin there is 
also a direct link between the sensory nervous system and a range 
of potential cutaneous target cells. 
To date, three principal neurokinin receptors have been de­
scribed, NK-1R, NK-2R, and NK-3R, which bind with high 
affinity to SP, substance K, and neurokinin B, respectively, al­
though there is considerable cross-reactivity between these ligands 
and receptors (Sasai and Nakanishi, 1989; Tsuchida et ai, 1990; 
Hershey et ai, 1991). Recent immunohistochemistry studies in our 
laboratory indicate that keratinocytes in the epidermis predomi­
nantly express the NK-2R, whereas dermal endothelial cells and 
mast cells express the NK-1R.l Thus, three potential target cells in 
the skin for neuroinflammation express appropriate receptors for 
released neuropeptides by cutaneous sensory fibers. 
In addition to released neuropeptides and appropriate target cell 
receptors, another key determinant of the neurogenic inflammatory 
response is the expression of neutral endopeptidase (NEP) (Kerr 
and Kenny, 1974; Bunnett, 1987). NEP is a principal protease for 
neurokinins such as SP and is believed to be an important regulator 
in terminating neurogenic inflammation (Borson et ai, 1989; Um­
eno et ai, 1989; Hwang et ai, 1993). When this cell membrane­
associated protolytic enzyme is located on the target cell that 
expresses the neurokinin receptors, it effectively competes for the 
released neuropeptides. Recent work in our laboratory indicates 
that in the skin significant NEP is detected in the epidermis and 
microvascular endothelial cells of the dermis. 1 Other studies dem­
onstrate that spontaneous vascular leakage and cutaneous edema 
occur in the dermis of NEP knockout mice, thereby supporting a 
role of this enzyme in preventing constitutive neurogenic inflam­
mation in the skin (Lu et ai, 1997). Thus, like all inflammatory 
processes, neurogenic inflammation is complicated and dependent 
on a number of factors including the types and quantities of released 
neuropeptides, the types of receptors on the target cells, NEP 
localization, activation state of the target cell, and the presence of 
other mediators of inflammation such as prostaglandins and cyto­
kines. 
1 Bunnett NW, Song IS, Grady EF, Harten]B, Olerud ]E, Armstrong 
CA, Payan DG, Ansel ]C: Localization of neurokinin receptors on trans­
fected cell lines, keratinocytes, and dermal microvascular endothelial cells. 
] Invest Dennatol106: 814, 1996 (abstr). 
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THE ROLE OF NEUROGENIC INFLAMMATION IN 
CLINICAL DISEASE 
There are a number of examples of clinical diseases that appear 10 
have a significant neurogenic component. These in�lude ophthal­
mic herpes virus infections , inflammatory bowel dIsease, asthma. 
and inflammatory arthritis (Jancso rt ai, 1985; Borson ft aI, 198� 
Hwang et ai, 1993). There is evidence of a neurogenic componem 
in the pathogenesis of urticaria, psoriasis, and atopic dermatitis. 
In the skin there is a close anatomic association of cutaneoU! 
nerves and mast cells, thus providing the physical link for these two 
systems to interact (Naukkarinen et ai, 1993). The ability of 
neuropeptides to activate mast cells and induce urticaria has been 
appreciated for a number of years (Church et ai, 1989). Investigaton 
have demonstrated that neurokinins such as SP are capable of 
binding to and directly activating mast cells and triggering the 
release of immediate hypersensitivity mediators (Baxter and Ad­
amik, 1978; Hartung and Toyka, 1983; Payan et ai, 1984). As will 
be discussed below, neurokinins may also be responsible for the 
release of mast cell cytokines that may mediate late phase inflam­
matory responses (Ansel et ai, 1993). 
A neurogenic component for the pathophysiology of psoriasil i! 
suggested by both clinical and experimental findings (Bernstein (f 
ai, 1986; Farber et ai, 1986; Giannetti and Girolomoni, 1989; 
Naukkarinen et ai, 1989; Pincelli et ai, 1990). Clinically, lesions 
often have a symmetrical distribution in regions that are trauma­
tized. The so-called Koebner phenomenon in psoriasis may be 
initiated by the release of pro-inflammatory neuropeptides in the 
traumatized skin (Farber et ai, 1986). Investigators have also 
reported increased levels of neuropeptides and sensory nerves in 
psoriatic skin lesions and capsaicin, a chemical that depletes neu­
ropeptides from nerve endings, has been reported to have some 
therapeutic value in clearing lesions (Bernstein et ai, 1986; Nauk­
karinen et ai, 1989). Likewise, in atopic dermatitis increased lesional 
staining of cutaneous nerves and abnormal cutaneous responses to 
injected neuropeptides have been reported (Giannetti and Girolo­
moni, 1989; Pincelli et ai, 1990). These types of prelintinary studies 
support, but do not prove, the potential involvement of the 
neurologic system in inflammatory skin diseases. 
THE ROLE OF THE NEUROLOGICAL SYSTEM IN 
WOUND HEALING 
Increasing data suggest that the neurologic system also may play an 
important role in mediating normal wound healing. Released 
neuropeptides may modulate a number of important aspects of 
normal wound healing such as cell proliferation, cytokine and 
growth factor production, and neovascularization (Nilsson et ai, 
1985; Payan, 1985; Nilsson et aI, 1986; Tanaka et ai, 1988; Brown 
et ai, 1990; Ziche et ai, 1990). Surgical resection of cutaneous nerves 
results in delayed wound healing in animal models (Kjartansson et 
ai, 1987; Lusthaus et aI, 1993). In addition, patients with cutaneous 
sensory defects due to lepromatous leprosy, spinal cord injury, and 
diabetic neuropathy develop ulcers that fail to heal in spite of 
aggressive wound care and wound protection (Olivari ef ai, 1972; 
Basson and Burney, 1982; Johnson and Doll, 1984). Experimental 
evidence indicates that the neurologic system also appears to have 
an important trophic effect for tissue integrity and function. For 
example, the destruction of the ophthalmic branch of the trigeminal 
nerve results in atrophy, scarring, and ulceration of the cornea 
(Duke-Elder and Leigh, 1965). Currently, a number of animal 
models exist that will allow us to test the role of the neurologic 
system in normal wound healing. Murine gene knockout models 
are currently available in which various components of the neuro­
genic inflammatory system have been deleted including cutaneous 
sensory nerves, neurokinins, neurokinin receptors, and neuropep­
tidases (Lee et ai, 1992; Lu et aI, 1995). These animals will allow us 
to examine the role of the neurologic system on cutaneous 
inflammation and wound healing in a well controlled experimental 
system. 
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Figure 1. SP induces expression of VCAM-1 by HDMEC in a 
dose-dependent fashion. Cultured HDMEC were treated with increas­
ing concentrations of SP (0.1, 1.0, 10, and 100 nM), or with TNFa (300 
units per ml) for 16 h and then assayed for VCAM-l expression by cell 
enzyme-linked immunosorbent assay. Values are expressed as OD 450 nM 
and represent the mean ± SD of quadruplicate analyses. 
NEUROPEPTIDE EFFECTS ON SPECIFIC TARGET CELLS 
Recent work in our laboratories has examined the effect of 
cutaneous neuropeptides on specific target cells in the skin. As 
previously mentioned, it has been established by a number of 
investigators that neuropeptides are capable of activating mast cells 
to release mediators of immediate hypersensitivity (Baxter and 
Adamik, 1978; Hartung and Toyka, 1983; Payan et aI, 1984). We 
have demonstrated that mast cells are also capable of secreting 
mediators of late phase inflammatory responses such as tumor 
necrosis factor a (TNFa) (Ansel et aI, 1993). SP is capable of 
inducing mast cell TNFa mRNA levels and increased secreted 
TNFa activity. This effect was not generalized inasmuch as SP did 
not a1fect mast cell interleukin-3 and interleukin-6 production. 
Thus, these studies support the role of the neurologic system in 
directly activating mast cells to produce cytokines such as TNFa, 
which may mediate delayed inflammatory responses in the skin. 
It has been noted that cutaneous sensory fibers extend directly 
into the epidermis, where they come in contact with both kerati­
nocytes and Langerhans cells (Dalsgaard et aI, 1989; Hosoi et aI, 
1993). We examined the possibility that released neurokinins may 
modulate cutaneous inflammation in part by the induction of 
keratinocyte cytokine production: We have reported that SP is 
capable of directly activating both murine and normal human 
keratinocytes to induce interleukin 1 (IL-1) production in a dose­
dependent manner (Brown et aI, 1990). This effect can be inhibited 
by specific neurokinin receptor antagonists. In a related in vivo 
study, normal human volunteers were treated topically with the 
neuropeptide-releasing agent, capsaicin, and IL-1 production in the 
epidermis was measured 12 h later by immunohistochemistry.2 As 
in the in vitro studies, we found significant IL-1 produced in the 
epidermis after the capsaicin induction of cutaneous neuropeptides. 
Thus, the release of neurokinins by cutaneous sensory nerves may 
mediate cutaneous inflammation in part by the induction of kera­
tinocyte pro-inflammatory cytokines. 
. 
Dermal microvascular endothelial cells are another potentially 
unportant target cell in cutaneous neurogenic inflammation. Cuta­
neous sensory fibers are found in close contact with dermal 
microvascular endothelial cells. We have examined the effect of 
cutaneous neuropeptides on two important inflammatory activities 
of endothelial cells: cytokine production and cellular adhesion 
molecule expression. Recent studies in our laboratory indicate that 
certain neuropeptides released by cutaneous c-fibers are capable of 
inducing interleukin 8 (IL-8) production in normal human dermal 
2 Sung K], AH Kaynard, Brown], Armstrong CA, Ansel]C: Neurokinin 
modulation of nonnal human keratinocyte cytokine production. J Invest 
Dermatoil0l:407, 1993 (abstr). 
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Figure 2. The kinetics of SP induction of HDMEC VCAM-1 ex­
pression. Cultured HDMEC were treated with SP (10 nM) for various 
amounts of time ranging from 1 to 24 h, or with TNFa (300 units per rul) 
for 16 h and then VCAM-l expression was measured by cell enzyme-linked 
immunosorbent assay. Values are expressed as OD 450 oM and represent 
the mean ± SD of quadruplicate analyses. 
microvascular endothelial cells (HDMEC).3 IL-8 is a principal 
chemotactic factor for neutrophils and facilitates their vascular 
transmigration. Increased IL-8 secretion and IL-8 immunoreactivity 
were detected in neuropeptide-activated HDMEC and in endothe­
lial cells in an ex vivo cultured skin explant system.4 The effect of 
cutaneous neuropeptides on HDMEC cellular adhesion molecules 
was also examined. Our studies indicate that HDMEC can be 
directly activated to express increased cellular adhesion molecules 
in a dose-dependent fashion in vitro and in vivo by neuropeptides 
such as SP. As shown in Fig 1, vascular cellular adhesion molecule 
1 (VCAM-1) is induced on the surface of cultured HDMEC by SP 
with maximum induction following treatment with 10 nM SP. 
Kinetics studies demonstrate that SP induction of VCAM-1 surface 
expression on HDMEC increases over time with maximal induction 
at 16 h (Fig 2). Thus, released cutaneous neurokinins can directly 
modulate dermal microvascular endothelial cell inflammatory ac­
tivities. 
CONCLUSION 
As our understanding of the interactions of the skin and nervous 
system continues to expand, it is likely that exciting, novel therapies 
will be developed to treat the inflammatory skin diseases that are 
mediated through neuroinflammation. Specific pharmacologic tar­
gets for the development of new agents will include the neuropep­
tides released in the skin, neuropeptide receptors expressed on 
target cells in the skin, proteases that degrade cutaneous neuropep­
tides, and growth factors that influence innervation in the skin. 
Thus, these approaches generate promise of more specific therapies 
for a wide range of chronic, debilitating infI.ammatory skin diseases. 
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